A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

British Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2009, Pages 690-699

  Mukonzo, Jackson K ^a,b   Röshammar, Daniel ^c   Waako, Paul ^b   Andersson, Maria ^a   Fukasawa, Takashi ^a   Milani, Lili ^d   Svensson, Jan Olof ^a   Ogwal Okeng, Jasper ^b   Gustafsson, Lars L ^a   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

ABCB1; CYP2B6; CYP3A5; Efavirenz; Population pharmacokinetics; Ugandans

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; EFAVIRENZ; MULTIDRUG RESISTANCE PROTEIN 1;

ABCB1 GENE; ADULT; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; GENE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENETICS; POPULATION MODEL; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; UGANDA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, GENETIC; POLYMORPHISM, GENETIC; SEX FACTORS; UGANDA; YOUNG ADULT;

EID: 70449334327     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03516.x     Document Type: Article

References (33)

1. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 2008 68 : 567 578.
2. Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics 2007 119 : e705 15.
3. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003 306 : 287 300.
4. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. A model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother 2009 53 : 2346 2353.
5. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, Schenk P, van Schaik R. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006 61 : 148 154.
6. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004 18 : 2391 2400.
7. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007 8 : 547 558.
8. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 2007 4 : 106 119.
9. Brundage RC, Yong FH, Fenton T, Spector SA, Starr SE, Fletcher CV. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 2004 48 : 979 984.
10. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003 73 : 20 30.
11. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003 47 : 130 137.
12. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C. High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008 64 : 357 365.
13. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr., Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 2005 192 : 1931 1942.
14. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. Aids 2005 19 : 371 380.
15. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids 2001 15 : 71 5.
16. Nunez M, Gonzalez de Requena D, Gallego L, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001 28 : 399 400.
17. Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A, Eriksen J, Herben VM, Jones BC, Gustafsson LL, Bertilsson L. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 2006 16 : 637 645.
18. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998 101 : 289 294.
19. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002 19 : 1038 1045.
20. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002 359 : 30 6.
21. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, Richeldi L, Mussini C, Esposito R, Cossarizza A. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. Aids 2003 17 : 1696 1698.
22. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 2003 8 : 531 534.
23. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980 8 : 553 571.
24. Lindroos K, Liljedahl U, Syvanen AC. Genotyping SNPs by minisequencing primer extension using oligonucleotide microarrays. Methods Mol Biol 2003 212 : 149 165.
25. Lovmar L, Syvanen AC. Genotyping single-nucleotide polymorphisms by minisequencing using tag arrays. Methods Mol Med 2005 114 : 79 92.
26. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002 12 : 437 450.
27. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001 69 : 169 174.
28. Beal SL, Sheiner LB, Boeckmann AJ, eds. NONMEM Users Guides. Ellicot City, MD : Icon Development Solutions, 1986-2006.
29. Wilkins JJ. NONMEMory: a run management tool for NONMEM. Comput Methods Programs Biomed 2005 78 : 259 267.
30. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999 58 : 51 64.
31. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res 2006 23 : 1144 1156.
32. Fayet A, Beguin A, de Tejada BM, Colombo S, Cavassini M, Gerber S, Eap CB, Telenti A, Buclin T, Biollaz J, Decosterd LA. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 2008 30 : 511 522.
33. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002 40 : 507 519.